Pre-operative β-blockade with propranolol reduces biomarkers of metastasis in breast cancer: a Phase II randomized trial.
The majority of deaths from breast cancer occur following the development of metastatic disease, a process inhibited by β-blockers in pre-clinical studies. This phase II randomized controlled trial evaluated the effect of pre-operative β-blockade with propranolol on biomarkers of metastatic potential and the immune cell profile within the primary tumor of patients with breast cancer. In this triple-blind placebo-controlled clinical trial, 60 patients were randomly assigned to receive an escalating dose of oral propranolol (n=30; 80-160 mg daily) or placebo (n=30) for seven days prior to surgery. The primary endpoint investigated the effect of propranolol on pro-metastatic and pro-inflammatory gene expression within the primary tumor. Propranolol down-regulated primary tumor expression of mesenchymal genes (P=0.002) without affecting epithelial gene expression (P=0.21). Bioinformatic analyses implicated down-regulation of Snail/Slug (P = 0.03), NF-κB/Rel (P < 0.01), and AP-1 (P < 0.01) transcription factors in structuring the observed transcriptome alterations, and identified changes in intra-tumoral neutrophil, NK cell, and dendritic cell recruitment (all P < 0.01). Patients with clinical evidence of drug response (lowered heart rate and blood pressure) demonstrated elevated tumor infiltration of CD68+ macrophages and CD8+ T cells. One week of β-blockade with propranolol reduced intra-tumoral mesenchymal polarization and promoted immune cell infiltration in early stage surgically-resectable breast cancer. These results show that β-blockade reduces biomarkers associated with metastatic potential, and support the need for larger phase III clinical trials powered to detect the impact of β-blockade on cancer recurrence and survival.